IVP Sample Clauses

IVP at its own cost, shall secure and carry insurance, covering itself and its employees providing services under this Agreement in the minimum amount of $1 million per incident, $3 million in the aggregate, for professional negligence and general liability. Such insurance shall name IPSI and IntegraMed as additional named insureds. IVP shall also carry a policy of public liability and property damage insurance with respect to the Facilities under which the insurer agrees to indemnify IPSI and IntegraMed, subject to ordinary deductibles, against all cost, expense, and/or liability arising out of or based upon any and all claims, accidents, injuries, and damages customarily included within the coverage of such policies of insurance available for IVP. The minimum limits of liability of such insurance shall be $1 million combined single limit covering bodily injury and property damage. IPSI and IntegraMed shall be additional named insureds under the terms of such insurance coverages. A certificate of insurance evidencing such policies shall be presented to IPSI within 30 days after the execution of this Agreement. Failure to provide such certificate(s) with such period shall constitute a material breach by IVP hereunder subject to the procedures of Section 9.1.2 above.
Sample 1Sample 2
AutoNDA by SimpleDocs
IVP. Identifying Vulnerable People is a model that was developed in the UK and it provides practitioners with a check list of behaviors that might lead to radicalization (Xxxx et al, 2016; p. 23). The guide contains 16 indicators, five of which are considered red flag indicators (Xxxxx, 2019; p. 25). It is easy to access and to use, but some of the indicators are relevant mostly in the case of Islamist extremism (ibid. 27). One research analyzing the IVP risk assessment tool finds it reliable and argues that it is a useful tool to identify those individuals who might be at risk of becoming extremists (Xxxx et al, 2016; p. 29).
Sample 1
IVP. (a) shall purchase for its own account at its own cost, and shall maintain in its own inventory, sufficient Pharmaceutical Products as may be necessary from time to time to satisfy IPSI'S Pharmaceutical Services in a timely fashion; (b) shall sell to IPSI, at the Cost of Pharmaceutical Products, only such Pharmaceutical Products as are necessary to fill the orders of Customers of the Medical Practices on a just-in-time basis; and (c) shall distribute such Pharmaceutical Products to Customers of the Medical Practices in accordance with all applicable laws and regulations and as prescribed by physicians associated with the Medical Practices. Cost of Pharmaceutical Products shall be paid by IPSI to IVP under the following schedule: Pharmaceutical Products sold during the first 15 days of a month shall be paid for on the 25th day of such month; Pharmaceutical Products sold during the 16th day through the end of the month shall be paid on the 10th day of the immediately succeeding month.
Sample 1
IVP shall arrange for the preparation of, and within 30 days following the end of each Fiscal Year shall present to IPSI, (a) a balance sheet, dated as of the last day of such Fiscal Year; (b) a cash flow statement showing the cash flows for the month and for the entire Fiscal Year then concluded; and (c) a statement showing the income and expenses of IPSI for the month and for the entire Fiscal Year then concluded. At the election of IntegraMed expressed in writing to IVP at least 90 days prior to the end of a Fiscal Year, the financial statements referred to in this Section 3.4 shall be audited by PriceWaterhouseCoopers or other independent certified public account approved by the JOB. IVP's failure to present annual financial statements to IPSI in accordance with this Section 3.4.1 within 45 days following the end of the Fiscal Year shall be deemed a material breach subject to Section 9.1.2 below.
Sample 1
IVP at its own cost, shall secure and carry insurance, covering itself and its employees providing services under this Agreement in the minimum amount of $1 million per incident, $3 million in the aggregate, for professional negligence and general liability. Such insurance shall name IntegraMed as an additional named insured. IVP shall also carry a policy of public liability and property damage insurance with respect to the Facilities under which the insurer agrees to indemnify IntegraMed, subject to ordinary deductibles, against all cost, expense, and/or liability arising out of or based upon any and all claims, accidents, injuries, and damages customarily included within the coverage of such policies of insurance available for IVP. The minimum limits of liability of such insurance shall be $1 million combined single limit covering bodily injury and property damage. IntegraMed shall be an additional named insured under the terms of such insurance coverages. A certificate of insurance evidencing such policies shall be presented to IntegraMed within 30 days after the execution of this Agreement. Failure to provide such certificate(s) with such period shall constitute a material breach by IVP hereunder subject to the procedures of Section 8.1.2 above.
Sample 1
IVP. (a) shall purchase and maintain in its inventory, sufficient Pharmaceutical Products as may be necessary from time to time to provide Pharmaceutical Services to Customers of the Medical Practices in a timely fashion; provided, however, a minimal inventory, not to exceed the dollar amount set forth on Exhibit 3.1.8 shall be maintained by IVP at all time during the Term of this Agreement; (b) shall invoice IPSI, at the Cost of Pharmaceutical Products, for such Pharmaceutical Products as are necessary to fill the orders of Customers of the Medical Practices; and (c) shall distribute such Pharmaceutical Products to Customers of the Medical Practices in accordance with all applicable laws and regulations and as prescribed by physicians associated with the Medical Practices. Cost of Pharmaceutical Products shall be paid by IPSI to IVP under the following schedule: Pharmaceutical Products shipped to Customers of Medical Practices during the first 15 days of a month shall be paid for on the 25th day of such month; Pharmaceutical Products shipped to Customers of the Medical Practice during the 16th day through the end of the month shall be paid on the 10th day of the immediately succeeding month.
Sample 1

Related to IVP

  • Independent Evaluation Buyer is experienced and knowledgeable in the oil and gas business. Buyer has been advised by and has relied solely on its own expertise and legal, tax, accounting, marketing, land, engineering, environmental and other professional counsel concerning this transaction, the Subject Property and value thereof.

  • Appraised Value If an Objecting Party objects in writing to the Initial Valuation within ten (10) days after its receipt of the Valuation Notice, the Objecting Party, within fourteen (14) days from the date of such written objection, shall engage an Independent Appraiser (the “First Appraiser”) to determine within thirty (30) days of such engagement the Fair Market Value of the Partnership Interests (the “First Appraised Value”). The cost of the First Appraiser shall be borne by the Objecting Party. If the First Appraised Value is at least eighty percent (80%) of the Initial Value and less than or equal to one hundred twenty percent (120%) of the Initial Value, then the Purchase Price shall be the average of the Initial Value and the First Appraised Value. If the First Appraised Value is less than eighty percent (80%) of the Initial Value or more than one hundred twenty percent (120%) of the Initial Value, then the Partnership and the Objecting Party shall, within fourteen (14) days from the date of the First Appraised Value, mutually agree on and engage a second Independent Appraiser (the “Final Appraiser”). The cost of the Final Appraiser shall be borne equally by the Partnership and the Objecting Party. The Final Appraiser shall determine within thirty (30) days after its engagement the Fair Market Value of the Partnership Interests, but if such determination is less than the lesser of the Initial Value and the First Appraised Value then the lesser of the Initial Value and the First Appraised value shall be the value or if such determination is greater than the greater of the Initial Value and the First Appraised Value then the greater of the Initial Value and the First Appraised Value shall be the value (the “Final Valuation”). The Purchase Price shall be equal to the Final Valuation and shall be final and binding upon the parties to this Agreement for purposes of the subject transaction.

  • Performance Appraisal The Executive’s performance may be evaluated by the Board of Directors or the Committee from time to time. The Executive shall be entitled to such additional remuneration, including but not limited to annual bonuses based on performance, as the Board of Directors or the Committee may, in its discretion, determine from time to time.

  • Performance Appraisals 3201 The Employer shall complete a written appraisal of a nurse's performance at least bi-annually. Upon request, the nurse shall be given an exact copy of the appraisal. 3202 The nurse shall have an opportunity to read such document. 3203 The nurse's signature on such document merely signifies that the contents of the document have been read. 3204 If the nurse disputes the appraisal, she/he may file a reply to the document in accordance with Article 29, and/or she/he may file a grievance under Article 12 of this Agreement.

  • Mileage Measurement Where required, the mileage measurement for LIS rate elements is determined in the same manner as the mileage measurement for V&H methodology as outlined in NECA Tariff No. 4.

  • EVALUATING PERFORMANCE 7.1 The Performance Plan (Annexure A) to this Agreement sets out:

  • Independent Analysis Each Party hereby confirms that its decision to execute this Agreement has been based upon its independent assessment of documents and information available to it, as it has deemed appropriate.

  • Covenants of Performance Measurement No interference. Registry Operator shall not interfere with measurement Probes, including any form of preferential treatment of the requests for the monitored services. Registry Operator shall respond to the measurement tests described in this Specification as it would to any other request from an Internet user (for DNS and RDDS) or registrar (for EPP). ICANN testing registrar. Registry Operator agrees that ICANN will have a testing registrar used for purposes of measuring the SLRs described above. Registry Operator agrees to not provide any differentiated treatment for the testing registrar other than no billing of the transactions. ICANN shall not use the registrar for registering domain names (or other registry objects) for itself or others, except for the purposes of verifying contractual compliance with the conditions described in this Agreement. PUBLIC INTEREST COMMITMENTS Registry Operator will use only ICANN accredited registrars that are party to the Registrar Accreditation Agreement approved by the ICANN Board of Directors on 27 June 2013 in registering domain names. A list of such registrars shall be maintained by ICANN on ICANN’s website. (Intentionally omitted. Registry Operator has not included commitments, statements of intent or business plans provided for in its application to ICANN for the TLD.) Registry Operator agrees to perform the following specific public interest commitments, which commitments shall be enforceable by ICANN and through the Public Interest Commitment Dispute Resolution Process established by ICANN (posted at xxxx://xxx.xxxxx.xxx/en/resources/registries/picdrp), which may be revised in immaterial respects by ICANN from time to time (the “PICDRP”). Registry Operator shall comply with the PICDRP. Registry Operator agrees to implement and adhere to any remedies ICANN imposes (which may include any reasonable remedy, including for the avoidance of doubt, the termination of the Registry Agreement pursuant to Section 4.3(e) of the Agreement) following a determination by any PICDRP panel and to be bound by any such determination. Registry Operator will include a provision in its Registry-Registrar Agreement that requires Registrars to include in their Registration Agreements a provision prohibiting Registered Name Holders from distributing malware, abusively operating botnets, phishing, piracy, trademark or copyright infringement, fraudulent or deceptive practices, counterfeiting or otherwise engaging in activity contrary to applicable law, and providing (consistent with applicable law and any related procedures) consequences for such activities including suspension of the domain name. Registry Operator will periodically conduct a technical analysis to assess whether domains in the TLD are being used to perpetrate security threats, such as pharming, phishing, malware, and botnets. Registry Operator will maintain statistical reports on the number of security threats identified and the actions taken as a result of the periodic security checks. Registry Operator will maintain these reports for the term of the Agreement unless a shorter period is required by law or approved by ICANN, and will provide them to ICANN upon request. Registry Operator will operate the TLD in a transparent manner consistent with general principles of openness and non-discrimination by establishing, publishing and adhering to clear registration policies.

  • Evaluation Criteria 5.2.1. The responses will be evaluated based on the following: (edit evaluation criteria below as appropriate for your project)

Time is Money Join Law Insider Premium to draft better contracts faster.